Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radafaxine in Major Depressive Disorder
NCT00057239Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2003
- Primary completion
- May 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of radafaxine in major depressive disorder (MDD) (3 arms), sponsored by GSK. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 8 weeks. Started Mar 2003; status: completed.
02
Drugs
radafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00057239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00057239.